世界科技研究与发展
世界科技研究與髮展
세계과기연구여발전
WORLD SCI-TECH R & D
2009年
5期
930-931
,共2页
瑞替普酶%尿激酶%急性心肌梗死
瑞替普酶%尿激酶%急性心肌梗死
서체보매%뇨격매%급성심기경사
Reteplase%Urokinas%acute myocardiai infraction
目的 对比观察瑞替普酶(reteplase rPA )与尿激酶用于急性心肌梗死(AMI) 溶栓治疗的效果.方法 从2006年10月到2008年10月,共收治38例AMI患者,随机接受r-PA或尿激酶溶栓治疗,观察溶栓再通率及不良反应发生率.结果 溶栓后2 h再通率rPA组为89.47%,尿激酶组68.42% (P＜0.01).结论 瑞替普酶治疗AMI再通率高,疗效确切,值得临床推广.
目的 對比觀察瑞替普酶(reteplase rPA )與尿激酶用于急性心肌梗死(AMI) 溶栓治療的效果.方法 從2006年10月到2008年10月,共收治38例AMI患者,隨機接受r-PA或尿激酶溶栓治療,觀察溶栓再通率及不良反應髮生率.結果 溶栓後2 h再通率rPA組為89.47%,尿激酶組68.42% (P＜0.01).結論 瑞替普酶治療AMI再通率高,療效確切,值得臨床推廣.
목적 대비관찰서체보매(reteplase rPA )여뇨격매용우급성심기경사(AMI) 용전치료적효과.방법 종2006년10월도2008년10월,공수치38례AMI환자,수궤접수r-PA혹뇨격매용전치료,관찰용전재통솔급불량반응발생솔.결과 용전후2 h재통솔rPA조위89.47%,뇨격매조68.42% (P＜0.01).결론 서체보매치료AMI재통솔고,료효학절,치득림상추엄.
Objective To observe the therapeutic effect of Reteplase and Urokinas in the treatment of acute myocardiai infarction(AMI).Method From October 2006 to October 2008, a total of 38 cases of AMI treated patients, randomly assigned to receive r-PA or Urokinas thrombolytic therapy, observe the recanalization rate of thrombolysis therapeutics and the incidence of adverse reaction rate. Result After. 2 hours, the recanalization rate of Reteplase group is 89.47% , the Urokinas group is 68.42% (P<0.01). Conclusion The recanalization rate of thrombolysis therapeutics of Reteplase in the AMI patients is higher, the therapeutic effect is accurate,and is worthy of clinical promotion.
